{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T01:35:58Z","timestamp":1794274558157,"version":"4.9.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T00:00:00Z","timestamp":1673827200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011112","name":"UCB Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011112","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.jns.2022.120531","type":"journal-article","created":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T05:19:57Z","timestamp":1671772797000},"page":"120531","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["A real-world analysis of factors associated with high healthcare resource utilization and costs in patients with myasthenia gravis receiving second-line treatment"],"prefix":"10.1016","volume":"445","author":[{"given":"Angela","family":"Ting","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler","family":"Story","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coralie","family":"Lecomte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adina","family":"Estrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar","family":"Syed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jns.2022.120531_bb0005","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat. Rev. Dis. Primers."},{"issue":"8","key":"10.1016\/j.jns.2022.120531_bb0010","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s00415-016-8045-z","article-title":"Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the guidelines of the German neurological society","volume":"263","author":"Melzer","year":"2016","journal-title":"J. Neurol."},{"key":"10.1016\/j.jns.2022.120531_bb0015","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1750-1172-2-44","article-title":"Myasthenia gravis","volume":"2","author":"Juel","year":"2007","journal-title":"Orphanet. J. Rare Dis."},{"issue":"1","key":"10.1016\/j.jns.2022.120531_bb0020","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/nyas.13522","article-title":"Myasthenia gravis: the role of complement at the neuromuscular junction","volume":"1412","author":"Howard","year":"2018","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jns.2022.120531_bb0025","doi-asserted-by":"crossref","first-page":"707","DOI":"10.3389\/fimmu.2020.00707","article-title":"Muscle-specific kinase myasthenia gravis","volume":"11","author":"Borges","year":"2020","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.jns.2022.120531_bb0030","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology."},{"issue":"5\u20136","key":"10.1016\/j.jns.2022.120531_bb0035","doi-asserted-by":"crossref","first-page":"428","DOI":"10.3109\/08916930903518107","article-title":"Immunosuppressive therapies in myasthenia gravis","volume":"43","author":"Sanders","year":"2010","journal-title":"Autoimmunity."},{"issue":"1","key":"10.1016\/j.jns.2022.120531_bb0040","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1177\/1941875210382918","article-title":"Myasthenic crisis","volume":"1","author":"Wendell","year":"2011","journal-title":"Neurohospitalist."},{"issue":"3","key":"10.1016\/j.jns.2022.120531_bb0045","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/mus.22327","article-title":"Estimated cost of treating myasthenia gravis in an insured U.S. population","volume":"45","author":"Guptill","year":"2012","journal-title":"Muscle Nerve"},{"issue":"3","key":"10.1016\/j.jns.2022.120531_bb0050","doi-asserted-by":"crossref","first-page":"376","DOI":"10.3988\/jcn.2019.15.3.376","article-title":"Examining the impact of refractory myasthenia gravis on healthcare resource utilization in the United States: analysis of a Myasthenia Gravis foundation of America patient registry sample","volume":"15","author":"Xin","year":"2019","journal-title":"J. Clin. Neurol."},{"issue":"Suppl","key":"10.1016\/j.jns.2022.120531_bb0055","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1136\/jnnp.57.Suppl.55","article-title":"Experience with intravenous immunoglobulin in myasthenia gravis: a review","volume":"57","author":"Edan","year":"1994","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"2","key":"10.1016\/j.jns.2022.120531_bb0060","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ncl.2018.01.011","article-title":"Treatment of myasthenia gravis","volume":"36","author":"Farmakidis","year":"2018","journal-title":"Neurol. Clin."},{"issue":"950","key":"10.1016\/j.jns.2022.120531_bb0065","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1136\/pgmj.2004.018903","article-title":"Update on myasthenia gravis","volume":"80","author":"Thanvi","year":"2004","journal-title":"Postgrad. Med. J."},{"key":"10.1016\/j.jns.2022.120531_bb0070","series-title":"Healthcare Resource Use in Myasthenia Gravis: a United States Health Claims Analysis","author":"Mahic","year":"2022"},{"key":"10.1016\/j.jns.2022.120531_bb0075","series-title":"Treatment Patterns in Myasthenia Gravis: A United States Health Claims Analysis","author":"Mahic","year":"2022"},{"issue":"4","key":"10.1016\/j.jns.2022.120531_bb0080","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00703-2018","article-title":"Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the literature","volume":"52","author":"Volmer","year":"2018","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.jns.2022.120531_bb0085","article-title":"Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study","volume":"357","author":"Waljee","year":"2017","journal-title":"BMJ."},{"key":"10.1016\/j.jns.2022.120531_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2019.116648","article-title":"Maintenance immunosuppression in myasthenia gravis, an update","volume":"410","author":"Morren","year":"2020","journal-title":"J. Neurol. Sci."},{"issue":"7","key":"10.1016\/j.jns.2022.120531_bb0095","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s40273-020-00912-8","article-title":"Economic costs of myasthenia gravis: a systematic review","volume":"38","author":"Landfeldt","year":"2020","journal-title":"Pharmacoeconomics."},{"issue":"12","key":"10.1016\/j.jns.2022.120531_bb0100","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1007\/s00296-017-3825-z","article-title":"Second-line treatment persistence and costs among patients with immune-mediated rheumatic diseases treated with subcutaneous TNF-alpha inhibitors","volume":"37","author":"Dal\u00e9n","year":"2017","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.jns.2022.120531_bb0105","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1186\/s12891-016-1102-z","article-title":"Treatment patterns and costs for anti-TNFalpha biologic therapy in patients with psoriatic arthritis","volume":"17","author":"Palmer","year":"2016","journal-title":"BMC Musculoskelet. Disord."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X22003938?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X22003938?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T16:00:45Z","timestamp":1758384045000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X22003938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":21,"alternative-id":["S0022510X22003938"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2022.120531","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A real-world analysis of factors associated with high healthcare resource utilization and costs in patients with myasthenia gravis receiving second-line treatment","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2022.120531","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 UCB Pharma. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"120531"}}